ESMO/X
Dec 12, 2024, 20:39
ESMO – RCTs have been instrumental in establishing immunotherapy with ICIs for treating Advanced Solid Cancer
ESMO shared on LinkedIn:
“ESMOImmuno24: Randomised controlled trials (RCTs) have been instrumental in establishing immunotherapy with immune checkpoint inhibitors (ICIs) for treating Advanced Solid Cancer. However, their stringent eligibility criteria often exclude many real-world patients, raising concerns about the generalisability of RCT results. Real-world data (RWD) can address these gaps by providing insights into the effectiveness and safety of ICIs in more diverse and representative patient populations. However, integrating Clinical Practice and regulatory decision-making faces challenges like data quality and consistency.
To learn more read the ESMO Daily Reporter editorial by Marco Donia. ”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 6, 2025, 21:28
Sep 6, 2025, 20:34
Sep 6, 2025, 20:20
Sep 6, 2025, 20:00
Sep 6, 2025, 19:13
Sep 6, 2025, 19:01